Vicente Villanueva, Daniel Santos-Carrasco, Pablo Cabezudo-García, Asier Gómez-Ibáñez, Mercedes Garcés, Pedro Serrano-Castro, Maria D Castro-Vilanova, Débora Sayas, Francisco J Lopez-Gonzalez, Xiana Rodríguez-Osorio, Gustavo Torres-Gaona, Rosa A Saiz-Diaz, Kevin G Hampel, Meritxell Martinez-Ferri, Maria J Aguilar-Amat, Blanca Mercedes-Alvarez, Vanessa García-Morales, Ana Del Villar-Igea, Andreu Massot-Tarrús, Juan J Rodríguez-Uranga
OBJECTIVE: This study investigated early, real-world outcomes with cenobamate (CNB) in a large series of patients with highly drug-resistant epilepsy within a Spanish Expanded Access Program (EAP). METHOD: This was a multicentre, retrospective, observational study in 14 hospitals. Inclusion criteria were age ≥18 years, focal seizures and EAP authorization. Data were sourced from patient clinical records. Primary effectiveness endpoints included reductions (100%, ≥90%, ≥75%, ≥50%) or worsening in seizure frequency at 3-, 6- and 12-month visits and at the last visit...
May 7, 2023: Epilepsia Open